Cognition Therapeutics, Inc. (CGTX)

1.9500 +0.0100 (+0.52%) 市場開市。 截至 03:55PM EDT。

Cognition Therapeutics, Inc.

2500 Westchester Ave.
Purchase, NY 10577
United States
412 481 2210
https://www.cogrx.com

版塊: Healthcare
行業: Biotechnology
全職員工: 25

高階主管

名稱	頭銜	支付	行使價	出生年份
Ms. Lisa Ricciardi	CEO, President & Director	854.15k	無	1960
Mr. John Brendan Doyle	Chief Financial Officer	414.88k	無	1977
Dr. Anthony O. Caggiano M.D., Ph.D.	Chief Medical Officer and Head of R&D	616.27k	無	1970
Dr. Steven A. Weissman Ph.D.	VP & Head of CMC	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

公司管治

截至 無 止，Cognition Therapeutics, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。